Telix Pharmaceuticals Limited Is A Global Biopharmaceutical Company Based In Australiafocused On Developing Diagnostic And Therapeutic Radiopharmaceuticalsknown As Theranosticsthe Company Aims To Enhance Precision Medicine Through Targeted Radiationimproving Patient Outcomes In Oncology And Rare Diseasestelix Is Publicly Listed On The Asx Under The Ticker Tlx The Companyae S Pipeline Includes Treatments For Urologic Oncologyneuro Oncologymusculoskeletal Oncologyand Bone Marrow Conditioningits Flagship Productilluccixa Is A Psma Pet Imaging Agent Approved For Detecting Prostate Cancer Metastases In Several Countriesincluding The U Sand Australiatelix Is Actively Conducting Over 18 Clinical Trials Worldwidereflecting Its Commitment To Advancing Cancer Care Led By Ceo Drchristian Behrenbruchtelix Prioritizes Patient Centric Innovation And Aims To Reduce The Toxicity Of Radiation Therapies While Improving Diagnostic Accuracythe Company Reported Significant Revenue Growthreaching $496 7 Million In 2023As It Continues To Expand Its Commercial Infrastructure And Regulatory Approvals For Its Products
